Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Lacouture

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 24, 2025
International survey on training of dermatology residents in supportive oncodermatology: the RESCUE studyAriadna Ortiz-Brugués, Davide Fattore, Marie Boileau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Cancer Discovery|November 15, 2015
Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsEli L Diamond, Benjamin H Durham, Julien Haroche, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 24, 2025
International survey on training of dermatology residents in supportive oncodermatology: the RESCUE studyAriadna Ortiz-Brugués, Davide Fattore, Marie Boileau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Cancer Discovery|November 15, 2015
Diverse and Targetable Kinase Alterations Drive Histiocytic NeoplasmsEli L Diamond, Benjamin H Durham, Julien Haroche, et al.
Pageof 6